Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several general statements about capecitabine are consistent with the drug label, but many specific safety, dosing, and administration claims (e.g., weight-based dosing, missed-dose timing, and side-effect frequency phrasing) are not verifiable from the provided label excerpts. The evaluation also does not address key label specifics about regimen-dependent dosing schedules and safety warnings beyond the provided sections.
Category Scores
Accurate Statements
“Tab capecitabine 500 mg” refers to a tablet containing capecitabine at a strength of 500 milligrams per tablet.
Not supported or verifiable from the provided label excerpts.
Capecitabine is an oral chemotherapy medicine.
Not supported or verifiable from the provided label excerpts.
Unsupported Statements
Capecitabine is used to treat certain cancers.
No label excerpt provided for approved indications.
Capecitabine is used to treat colorectal cancer.
No label excerpt provided for approved indications.
Capecitabine is used to treat breast cancer.
No label excerpt provided for approved indications.
Capecitabine is used to treat gastric (stomach) cancer.
No label excerpt provided for approved indications.
Capecitabine dosing is weight-based.
No dosing description or basis (e.g., mg/m^2 or weight-based) provided in the supplied label excerpts.
Capecitabine dosing depends on the treatment regimen.
No regimen-specific dosing details are included in the supplied label excerpts.
Many prescriptions use tablets of 500 mg.
No label excerpt provided about available tablet strengths or prescribing patterns.
The dose schedule (days on vs days off, and morning/evening timing) determines the exact dose to take.
No schedule/timing instructions or regimen patterns provided in the supplied label excerpts.
Common side effects of capecitabine include diarrhea.
No adverse reaction frequency/listing excerpt provided (only DPD-related toxicity examples are provided).
Common side effects of capecitabine include nausea or vomiting.
No adverse reaction frequency/listing excerpt provided.
Common side effects of capecitabine include mouth sores.
“Mucositis” is mentioned as an example of acute early-onset toxicity with complete DPD deficiency, but the claim is phrased as “common side effects,” which is not supported by the provided excerpts.
Common side effects of capecitabine include hand-foot syndrome (pain/redness/swelling of palms/soles).
No hand-foot syndrome adverse reaction excerpt provided.
Common side effects of capecitabine include low blood counts.
Neutropenia is mentioned as an example of serious/fatal DPD-related toxicity, but the claim is phrased as “common side effects,” which is not supported by the provided excerpts.
Low blood counts from capecitabine can lead to higher infection risk.
Not explicitly stated in the provided excerpts (neutropenia is mentioned, but infection risk causality is not provided).
Low blood counts from capecitabine can lead to anemia.
Anemia is not mentioned in the provided excerpts.
Low blood counts from capecitabine can lead to bleeding.
Bleeding is addressed in the provided excerpts specifically in the context of vitamin K antagonists/INR, not generally from “low blood counts.”
Because capecitabine is chemotherapy, safety rules are strict.
No label excerpt supports this generalization.
Capecitabine should be taken exactly as instructed on the prescription label.
No patient dosing instruction excerpt provided.
A patient should not change the dose or timing of capecitabine without their oncology team.
No dose modification counseling excerpt provided.
If a capecitabine dose is missed, instructions for missed doses should be followed as given by the doctor or pharmacist.
No missed-dose guidance excerpt provided.
The correct approach to missed capecitabine doses can vary by regimen.
No missed-dose/regimen guidance excerpt provided.
Capecitabine availability is generally through generics and brands depending on the market.
No label excerpt provided on market availability.
Contradictions
Low
AI Statement
Many prescriptions use tablets of 500 mg.
Label Reference
No contradiction can be assessed because the provided label excerpts do not address tablet strength availability.
Important Omissions
DPYD/DPD deficiency testing specifics are not addressed by the claims list itself; therefore key label details about avoiding use in complete DPD deficiency, withholding/discontinuation guidance, and test availability limitations are omitted.
Importance:
Moderate
INR monitoring and dose adjustment counseling for vitamin K antagonists (warfarin) is not included among the provided claims, despite being directly covered in the supplied label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple claims about dosing/timing and side effects are not verifiable from the provided prescribing information excerpts, increasing the chance of inaccurate counseling. The provided excerpted safety information about DPD deficiency and warfarin/INR bleeding risk is not incorporated into the claims list.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Indications, dosing basis/timing, missed-dose instructions, and adverse reaction frequency details are not supported by the supplied label excerpts, and key label safety counseling (DPYD/DPD and INR/warfarin) is omitted.
Suggested Improvement
Remove or rephrase statements that are not directly supported by the provided label text. For safety, incorporate label-specific DPD/DPYD testing/avoidance and vitamin K antagonist/INR monitoring language shown in the excerpts (Sections 5.1, 2.1, 5.2, 7.2, and 17).